tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2020 Sep 5.
doi: 10.1111/irv.12780. Online ahead of print.
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
Damien Friel[SUP] 1 [/SUP], Mary Co[SUP] 2 [/SUP], Thierry Ollinger[SUP] 1 [/SUP], Bruno Salaun[SUP] 3 [/SUP], Anne Schuind[SUP] 4 [/SUP], Ping Li[SUP] 5 [/SUP], Karl Walravens[SUP] 1 [/SUP], Francis A Ennis[SUP] 2 [/SUP], David W Vaughn[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Non-neutralizing antibodies inducing complement-dependent lysis (CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity may contribute to protection against influenza infection. We investigated CDL and ADCC responses in healthy adults randomized to receive either non-adjuvanted or AS03-adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 ?g/3.75 μg of hemagglutinin, respectively) on a 2-dose schedule 21 days apart.
Methods: We conducted an exploratory analysis of a subset of 106 subjects having no prior history of A(H1N1)pdm09 infection or seasonal influenza vaccination enrolled in a previously reported study (NCT00985673). Antibody responses against the homologous A/California/7/2009 (H1N1) vaccine strain and a related A/Brisbane/59/2007 (H1N1) seasonal influenza strain were analyzed up to Day 42.
Results: Baseline seropositivity determined with hemagglutination inhibition (HI), CDL and ADCC antibody titers against viral strains was high; A/California/7/2009 (HI [40.4-48.1%]; CDL [34.6-36.0%]; ADCC [92.1-92.3%]); A/Brisbane/59/2007 (HI [73.1-88.9%]; CDL [38.0-42.0%]; ADCC [86.8-97.0%]). CDL seropositivity increased following vaccination with both adjuvanted and non-adjuvanted formulations (A/California/7/2009 [95.9-100%]; A/Brisbane/59/2007 [75.5-79.6%]). At Day 21, increases in CDL and ADCC antibody geometric mean titers against both strains were observed for both formulations. After 2 doses of AS03-adjuvanted vaccine, vaccine responses of 95.8% (≥9-fold increase from baseline in CDL titers) and 34.3% (≥16-fold increase from baseline in ADCC titers) were seen against A/California/7/2009; and 22.4% and 42.9%, respectively, against A/Brisbane/59/2007. Vaccine responses after 2 doses of the non-adjuvanted vaccine were broadly similar.
Conclusions: Broadly comparable non-neutralizing immune responses were observed following vaccination with non-adjuvanted and AS03-adjuvanted A(H1N1)pdm09 formulations; including activity against a related vaccine strain.
Keywords: A(H1N1)pdm09 vaccine; AS03 adjuvant system; cross-reactivity; non-neutralizing antibodies.
. 2020 Sep 5.
doi: 10.1111/irv.12780. Online ahead of print.
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
Damien Friel[SUP] 1 [/SUP], Mary Co[SUP] 2 [/SUP], Thierry Ollinger[SUP] 1 [/SUP], Bruno Salaun[SUP] 3 [/SUP], Anne Schuind[SUP] 4 [/SUP], Ping Li[SUP] 5 [/SUP], Karl Walravens[SUP] 1 [/SUP], Francis A Ennis[SUP] 2 [/SUP], David W Vaughn[SUP] 4 [/SUP]
Affiliations
- PMID: 32889792
- DOI: 10.1111/irv.12780
Abstract
Background: Non-neutralizing antibodies inducing complement-dependent lysis (CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity may contribute to protection against influenza infection. We investigated CDL and ADCC responses in healthy adults randomized to receive either non-adjuvanted or AS03-adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 ?g/3.75 μg of hemagglutinin, respectively) on a 2-dose schedule 21 days apart.
Methods: We conducted an exploratory analysis of a subset of 106 subjects having no prior history of A(H1N1)pdm09 infection or seasonal influenza vaccination enrolled in a previously reported study (NCT00985673). Antibody responses against the homologous A/California/7/2009 (H1N1) vaccine strain and a related A/Brisbane/59/2007 (H1N1) seasonal influenza strain were analyzed up to Day 42.
Results: Baseline seropositivity determined with hemagglutination inhibition (HI), CDL and ADCC antibody titers against viral strains was high; A/California/7/2009 (HI [40.4-48.1%]; CDL [34.6-36.0%]; ADCC [92.1-92.3%]); A/Brisbane/59/2007 (HI [73.1-88.9%]; CDL [38.0-42.0%]; ADCC [86.8-97.0%]). CDL seropositivity increased following vaccination with both adjuvanted and non-adjuvanted formulations (A/California/7/2009 [95.9-100%]; A/Brisbane/59/2007 [75.5-79.6%]). At Day 21, increases in CDL and ADCC antibody geometric mean titers against both strains were observed for both formulations. After 2 doses of AS03-adjuvanted vaccine, vaccine responses of 95.8% (≥9-fold increase from baseline in CDL titers) and 34.3% (≥16-fold increase from baseline in ADCC titers) were seen against A/California/7/2009; and 22.4% and 42.9%, respectively, against A/Brisbane/59/2007. Vaccine responses after 2 doses of the non-adjuvanted vaccine were broadly similar.
Conclusions: Broadly comparable non-neutralizing immune responses were observed following vaccination with non-adjuvanted and AS03-adjuvanted A(H1N1)pdm09 formulations; including activity against a related vaccine strain.
Keywords: A(H1N1)pdm09 vaccine; AS03 adjuvant system; cross-reactivity; non-neutralizing antibodies.